Recro Pharma, Inc. REPH
At closeMar 22, 2022, 12:00 AM EDT
52-week range unavailable
- Market cap
- 177.42M
- Revenue (ttm)
- 75.36M
- Profit margin
- -15.09%
- Shares out
- 56.42M
- Forward P/E
- -11.61
- Volume
- 137.54K
- Open
- 2.07
- Previous close
- 2.09
- Day's range
- 2.00 – 2.14
- Analysts
- Strong Buy
- Price target
- 5.00 (+139.2%)
- Earnings date
- May 5, 2022
Key statistics
- Enterprise value
- 171.67M
- PEG ratio
- -0.61
- Price / sales
- 1.64
- Price / book
- 2.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 125.00%
- Free cash flow
- -468.25K
- Total cash
- 25.22M
- Total debt
- 103.52M
- Return on equity
- -81.32%
- Short % of float
- 1.26%
- 50-day average
- 1.73
- 200-day average
- 1.88
Analyst view
Consensus: strong buy
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 5, 2022
Expected May 5, 2022. Consensus EPS estimate -0.09.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 5, 2022 | Mar 1, 2022 | -0.04 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -0.07 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.05 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 26, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2021 | William Blair | init | — | Outperform |
| May 12, 2020 | Oppenheimer | main | — | Outperform |
| Mar 5, 2020 | Stephens & Co. | main | — | Overweight |
| Nov 26, 2019 | Stephens & Co. | main | — | Overweight |
| Oct 17, 2019 | Stephens & Co. | init | — | Overweight |
| Mar 25, 2019 | Roth Capital | down | Buy | Neutral |
About Recro Pharma, Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- recrocdmo.com
News
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript 
Earnings Scheduled For March 1, 2022 
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022 
Recro to Present at H.C. Wainwright BioConnect 2022 Conference 
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't? 
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript 
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data 
Earnings Scheduled For November 9, 2021 
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic 
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Your note
Sign in to keep a note on REPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM L | Director | Stock Award(Grant) | Apr 19, 2021 | 80,280 |
| AWM INVESTMENT COMPANY, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 20, 2021 | 0 |
| BERELOWITZ MICHAEL | Director | Stock Award(Grant) | Apr 19, 2021 | 76,546 |
| CHURCHILL WINSTON J. JR. | Director | Stock Award(Grant) | Apr 19, 2021 | 77,982 |
| ENLOE J DAVID JR | Chief Executive Officer | Purchase | Mar 14, 2022 | 524,879 |
| HENWOOD GERALDINE A | Director | Stock Award(Grant) | Apr 19, 2021 | 276,574 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 9.01% | 5,081,901 | 8.69M | Dec 30, 2021 |
| Cowen Prime Advisors LLC | 7.45% | 4,204,000 | 7.19M | Dec 30, 2021 |
| Samjo Capital LLC | 5.67% | 3,200,000 | 5.47M | Dec 30, 2021 |
| Athyrium Capital Management, LP | 3.90% | 2,202,420 | 3.77M | Dec 30, 2021 |
| Alyeska Investment Group, L.P. | 3.18% | 1,796,720 | 3.07M | Dec 30, 2021 |
| Vanguard Group, Inc. (The) | 3.00% | 1,694,462 | 2.90M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 1,130,309 | 1.93M | Dec 30, 2021 |
| Buffalo Early Stage Growth Fund | 1.22% | 690,000 | 1.18M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 0.84% | 472,521 | 808.01K | Dec 30, 2021 |
| First Eagle Small Opportunity Fund | 0.38% | 214,775 | 418.81K | Oct 30, 2021 |
| Fidelity Extended Market Index Fund | 0.38% | 213,994 | 365.93K | Dec 30, 2021 |
| Russell Inv Co-U.S. Small Cap Equity Fund | 0.24% | 136,069 | 265.33K | Oct 30, 2021 |